Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Navenibart Vial/Syringe vs Autoinjector in Healthy Volunteers
NCT07635095Phase 1Recruiting
- Sponsor
- Astria Therapeutics
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of navenibart in hereditary angioedema (HAE) (2 arms), sponsored by Astria Therapeutics. Primary endpoints: Maximum concentration up to 84 days and Area under the concentration versus time curve from time 0 to 84 days. Started Apr 2026; status: recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07635095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635095.